Matthew L. Maddess

Statistics

Publications

Citations

H-Index

Active since

2001

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

University of Toronto

Lovelace Respiratory Research Institute

Denali Therapeutics (United States)

University of Cambridge

Matthew L. Maddess is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, medicinal chemistry, and pharmacy.

ORCID

Publications per year

2001–2023

Publications

Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer

Wonsuk Chang, Michael D. Altman, Charles A. Lesburg et al. · Journal of Medicinal Chemistry · 2022 · 137 citations · Full text

Pharmacy, Oncology, Pharmacology +17

A kinase-cGAS cascade to synthesize a therapeutic STING activator

John A. McIntosh, Zhijian Liu, Brian M. Andresen et al. · Nature · 2022 · 135 citations

Life Sciences, Molecular Biology, Pharmacology +10

LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits

Marco A. S. Baptista, Kalpana Merchant, Ted Barrett et al. · Science Translational Medicine · 2020 · 130 citations

Medicine, Pharmacology, Pharmacotherapy +9

Modeling a Crowdsourced Definition of Molecular Complexity

Robert P. Sheridan, Nicolas F. Zorn, Edward C. Sherer et al. · Journal of Chemical Information and Modeling · 2014 · 86 citations

Pharmacy, Chemistry, Computational Chemistry +16

Total Synthesis of Rapamycin

Steven V. Ley, Miles N. Tackett, Matthew L. Maddess et al. · Chemistry - A European Journal · 2009 · 63 citations

Medicine, Medicinal Chemistry, Pharmacology +15

1–5 of 20